Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Tokyo Electric Power Company announced it has successfully completed the trial removal of a sample of fuel debris from the primary containment vessel of unit 2 at the damaged Fukushima Daiichi nuclear ...